INBRX-109 in Ewing Sarcoma & SDH-deficient GIST

 

Trial name: INBRX-109 in Ewing sarcomas and SDH-deficient GIST
Agents: INBRX-109 in combination with different therapies
Phase I
Status Recruiting
Sponsor Inhibrx, Inc.

This is a first-in-human, open-label, non-randomized phase 1 trial of INBRX-109 for patients with locally advanced or metastatic solid tumors including certain subtypes of sarcomas and GIST.

Further information can be found on clinicaltrials.gov.

 

WHO is the trial for?
  • Patients (age 12-85) with advanced or metastatic Ewing sarcomas which is progressing and has been pre-treated with 1-2 chemotherapies
  • Adult patients with advanced/metastatic SDH-deficient GIST (age 18-85) that is progressing. Previous treatment with TMZ is allowed.

WHAT is the key question that this trial is attempting to answer?

 The study aims to evaluate the safety, optimal dose, and preliminary effectiveness of INBRX-109, a novel therapeutic antibody.

WHY patients might want to participate?

 This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in sarcoma and potentially help other patients with this disease.

The trial might or might not have benefit in your individual case.

WHEN will the trial be open?

 The study is open for recruitment.

WHERE is the trial available?

 The trial is currently active in the US, Italy, France, Spain and the UK.

Please check for current information here.

Study contact: clinicaltrials@inhibrx.com

STUDY DESIGN: What does the study look like?

 This is an open-label Phase 1 trial, meaning all participants receive the investigational drug. It focuses on assessing safety and dosage in different cohorts, including sarcoma-specific groups, before expanding into broader efficacy evaluation.

HOW do I get more information?

 Patient organizations supporting sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organizations serving sarcoma patients. If there are no such organization in your country, please email us for more information: info@sarcoma-patients.org

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken